Cargando…
Commentary: Cost-Effectiveness of Left Ventricular Assist Devices as Destination Therapy in the United Kingdom
Autores principales: | Faldu, Priyansh, Sharma, Kamal, Sharma, Shaival, Ramani, Smeet, Dadhania, Nain, Konat, Ashwati |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312126/ https://www.ncbi.nlm.nih.gov/pubmed/35898270 http://dx.doi.org/10.3389/fcvm.2022.916588 |
Ejemplares similares
-
Commentary: Beyond 10-year risk: A cost-effectiveness analysis of statins for the primary prevention of cardiovascular disease
por: Shah, Aditya, et al.
Publicado: (2022) -
Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy
por: Rawal, Shalin, et al.
Publicado: (2022) -
Repostioning of Telemedicine in Cardiovascular World Post-COVID-19 Pandemic
por: Sharma, Kamal, et al.
Publicado: (2022) -
Pathophysiology and management of valvular disease in patients with destination left ventricular assist devices
por: Dimarakis, Ioannis, et al.
Publicado: (2022) -
Cost‐effectiveness of left ventricular assist devices as destination therapy in the United Kingdom
por: Schueler, Stephan, et al.
Publicado: (2021)